The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy

被引:10
作者
Lo, Chien-Ming [1 ]
Wang, Yu-Ming [2 ]
Chen, Yen-Hao [3 ]
Fang, Fu-Min [2 ]
Huang, Shun-Chen [4 ]
Lu, Hung-, I [1 ]
Li, Shau-Hsuan [3 ]
机构
[1] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Thorac & Cardiovasc Surg, Kaohsiung 833401, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung 833401, Taiwan
[3] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Hematol Oncol, Kaohsiung 833401, Taiwan
[4] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 833401, Taiwan
关键词
esophageal squamous cell carcinoma; chemoradiotherapy; esophagectomy; radiotherapy dose; PHASE-III TRIAL; NEOADJUVANT CHEMORADIATION; SURGERY; CANCER; CHEMOTHERAPY; SURVIVAL; THERAPY;
D O I
10.3390/curroncol28020129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: For patients with esophageal squamous cell carcinoma, preoperative chemoradiotherapy followed by planned esophagectomy is used as a curative treatment modality. However, the impact of radiotherapy dose remains undefined. Method: A total of 141 patients with stage III esophageal squamous cell carcinoma (ESCC; as defined by the 7th American Joint Committee on Cancer), receiving preoperative chemoradiotherapy followed by esophagectomy between 2000 and 2015 at Kaohsiung Chang Gung Memorial Hospital, Taiwan, were retrospectively reviewed. The radiotherapy dose of preoperative chemoradiotherapy (36 Gy before 2009 and 50-50.4 Gy after 2009) and other clinicopathological parameters were collected and correlated with the response to chemoradiotherapy and treatment outcome. Result: Of these 141 patients, the radiotherapy dose was 36 Gy in 59 (42%) patients and 50 Gy in 82 (58%) patients. A complete pathological response was noted in 12 (20%) of 59 patients receiving 36 Gy radiotherapy, and 37 (45%) of 82 patients receiving 50 Gy radiotherapy (p = 0.002). The three-year overall survival and disease-free survival rates were 31% and 25% in patients receiving 36 Gy radiotherapy, and 54% and 46% in patients receiving 50-50.4 Gy radiotherapy, respectively (p = 0.023 for overall survival; p = 0.047 for disease-free survival). Multivariate analysis showed that a higher radiotherapy dose was associated with increased pathological complete response (p = 0.003, hazard ratio: 3.215), better overall survival (p = 0.024, hazard ratio: 1.585), and superior disease-free survival (p = 0.049, hazard ratio: 1.493). However, higher radiotherapy doses revealed more surgical complications, including acute respiratory distress syndrome (p = 0.048) and anastomosis leaks (p = 0.004). Conclusion: For patients with locally advanced ESCC, preoperative chemoradiotherapy with higher radiotherapy doses led to increased pathologic complete response rates and improved survival.
引用
收藏
页码:1354 / 1365
页数:12
相关论文
共 26 条
  • [1] Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
  • [2] Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
    Bosset, JF
    Gignoux, M
    Triboulet, JP
    Tiret, E
    Mantion, G
    Elias, D
    Lozach, P
    Ollier, JC
    Pavy, JJ
    Mercier, M
    Sahmoud, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) : 161 - 167
  • [3] Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
    Burmeister, BH
    Smithers, BM
    Gebski, V
    Fitzgerald, L
    Simes, RJ
    Devitt, P
    Ackland, S
    Gotley, DC
    Joseph, D
    Millar, J
    North, J
    Walpole, ET
    Denham, JW
    [J]. LANCET ONCOLOGY, 2005, 6 (09) : 659 - 668
  • [4] Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis
    Engel, Steven
    Awerbuch, Adam
    Kwon, Deukwoo
    Picado, Omar
    Yechieli, Raphael
    Yakoub, Danny
    Portelance, Lorraine
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (03) : 391 - 399
  • [5] The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival An International Multicenter Cohort Study
    Fransen, Laura F. C.
    Berkelmans, Gijs H. K.
    Asti, Emanuele
    Henegouwen, Mark I. van Berge
    Berlth, Felix
    Bonavina, Luigi
    Brown, Andrew
    Bruns, Christiane
    van Daele, Elke
    Gisbertz, Suzanne S.
    Grimminger, Peter P.
    Gutschow, Christian A.
    Hannink, Gerjon
    Holscher, Arnulf H.
    Kauppi, Juha
    Lagarde, Sjoerd M.
    Mercer, Stuart
    Moons, Johnny
    Nafteux, Philippe
    Nilsson, Magnus
    Palazzo, Francesco
    Pattyn, Piet
    Raptis, Dimitri A.
    Rasanen, Jari
    Rosato, Ernest L.
    Rouvelas, Ioannis
    Schmidt, Henner M.
    Schneider, Paul M.
    Schroder, Wolfgang
    van der Sluis, Pieter C.
    Wijnhoven, Bas P. L.
    Nieuwenhuijzen, Grard A. P.
    Luyer, Misha D. P.
    [J]. ANNALS OF SURGERY, 2021, 274 (06) : E1129 - E1137
  • [6] Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers
    Fujita, H
    Sueyoshi, S
    Tanaka, T
    Tanaka, Y
    Sasahara, H
    Shirouzu, K
    Suzuki, G
    Hayabuchi, N
    Inutsuka, H
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2005, 90 (04) : 209 - 219
  • [7] Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
    Gebski, Val
    Burmeister, Bryan
    Smithers, B. Mark
    Foo, Kerwyn
    Zalcberg, John
    Simes, John
    [J]. LANCET ONCOLOGY, 2007, 8 (03) : 226 - 234
  • [8] Treatment outcomes of resected esophageal cancer
    Hofstetter, W
    Swisher, SG
    Correa, AM
    Hess, K
    Putnam, JB
    Ajani, JA
    Dolormente, M
    Francisco, R
    Komaki, RR
    Lara, A
    Martin, F
    Rice, DC
    Sarabia, AJ
    Smythe, WR
    Vaporciyan, AA
    Walsh, GL
    Roth, JA
    [J]. ANNALS OF SURGERY, 2002, 236 (03) : 376 - 385
  • [9] Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy
    Koeter, Marijn
    van der Sangen, Maurice J. C.
    Hurkmans, Coen W.
    Luyer, Misha D. P.
    Rutten, Harm J. T.
    Nieuwenhuijzen, Grard A. P.
    [J]. RADIATION ONCOLOGY, 2015, 10
  • [10] A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
    Lee, JL
    Park, SI
    Kim, SB
    Jung, HY
    Lee, GH
    Kim, JH
    Song, HY
    Cho, KJ
    Kim, WK
    Lee, JS
    Kim, SH
    Min, YI
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (06) : 947 - 954